Logo image of TSRI

TSR INC (TSRI) Stock Fundamental Analysis

NASDAQ:TSRI - Nasdaq - US8728852075 - Common Stock - Currency: USD

13.38  +0.01 (+0.04%)

After market: 13.3584 -0.02 (-0.16%)

Fundamental Rating

5

Overall TSRI gets a fundamental rating of 5 out of 10. We evaluated TSRI against 83 industry peers in the IT Services industry. While TSRI has a great health rating, its profitability is only average at the moment. TSRI is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year TSRI was profitable.
TSRI had a positive operating cash flow in the past year.
In multiple years TSRI reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: TSRI reported negative operating cash flow in multiple years.
TSRI Yearly Net Income VS EBIT VS OCF VS FCFTSRI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M 6M

1.2 Ratios

TSRI's Return On Assets of 7.75% is fine compared to the rest of the industry. TSRI outperforms 76.83% of its industry peers.
The Return On Equity of TSRI (10.80%) is better than 71.95% of its industry peers.
TSRI's Return On Invested Capital of 7.89% is fine compared to the rest of the industry. TSRI outperforms 68.29% of its industry peers.
The Average Return On Invested Capital over the past 3 years for TSRI is significantly below the industry average of 22.73%.
The last Return On Invested Capital (7.89%) for TSRI is above the 3 year average (5.05%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.75%
ROE 10.8%
ROIC 7.89%
ROA(3y)10.96%
ROA(5y)3.33%
ROE(3y)15.7%
ROE(5y)1.83%
ROIC(3y)5.05%
ROIC(5y)N/A
TSRI Yearly ROA, ROE, ROICTSRI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40

1.3 Margins

TSRI's Profit Margin of 2.15% is in line compared to the rest of the industry. TSRI outperforms 56.10% of its industry peers.
TSRI's Profit Margin has improved in the last couple of years.
TSRI has a Operating Margin (2.34%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of TSRI has grown nicely.
TSRI has a worse Gross Margin (17.57%) than 92.68% of its industry peers.
In the last couple of years the Gross Margin of TSRI has grown nicely.
Industry RankSector Rank
OM 2.34%
PM (TTM) 2.15%
GM 17.57%
OM growth 3YN/A
OM growth 5Y13.97%
PM growth 3YN/A
PM growth 5Y16.86%
GM growth 3Y3.5%
GM growth 5Y1.53%
TSRI Yearly Profit, Operating, Gross MarginsTSRI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10 15

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TSRI is destroying value.
The number of shares outstanding for TSRI has been reduced compared to 1 year ago.
TSRI has more shares outstanding than it did 5 years ago.
TSRI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TSRI Yearly Shares OutstandingTSRI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
TSRI Yearly Total Debt VS Total AssetsTSRI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

An Altman-Z score of 8.47 indicates that TSRI is not in any danger for bankruptcy at the moment.
The Altman-Z score of TSRI (8.47) is better than 90.24% of its industry peers.
There is no outstanding debt for TSRI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.47
ROIC/WACC0.77
WACC10.19%
TSRI Yearly LT Debt VS Equity VS FCFTSRI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M 10M 15M

2.3 Liquidity

TSRI has a Current Ratio of 3.37. This indicates that TSRI is financially healthy and has no problem in meeting its short term obligations.
TSRI's Current ratio of 3.37 is amongst the best of the industry. TSRI outperforms 81.71% of its industry peers.
A Quick Ratio of 3.37 indicates that TSRI has no problem at all paying its short term obligations.
TSRI's Quick ratio of 3.37 is amongst the best of the industry. TSRI outperforms 81.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.37
Quick Ratio 3.37
TSRI Yearly Current Assets VS Current LiabilitesTSRI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.48% over the past year.
The Earnings Per Share has been growing by 24.57% on average over the past years. This is a very strong growth
The Revenue for TSRI has decreased by -13.51% in the past year. This is quite bad
Measured over the past years, TSRI shows a quite strong growth in Revenue. The Revenue has been growing by 9.30% on average per year.
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5Y24.57%
EPS Q2Q%377.5%
Revenue 1Y (TTM)-13.51%
Revenue growth 3Y19.72%
Revenue growth 5Y9.3%
Sales Q2Q%-18.78%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TSRI Yearly Revenue VS EstimatesTSRI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.56 indicates a correct valuation of TSRI.
75.61% of the companies in the same industry are more expensive than TSRI, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.86, TSRI is valued a bit cheaper.
Industry RankSector Rank
PE 15.56
Fwd PE N/A
TSRI Price Earnings VS Forward Price EarningsTSRI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

TSRI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TSRI is cheaper than 84.15% of the companies in the same industry.
84.15% of the companies in the same industry are more expensive than TSRI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.32
EV/EBITDA 7.99
TSRI Per share dataTSRI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.63
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TSRI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TSR INC

NASDAQ:TSRI (6/28/2024, 8:00:01 PM)

After market: 13.3584 -0.02 (-0.16%)

13.38

+0.01 (+0.04%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)04-10 2024-04-10/amc
Earnings (Next)08-09 2024-08-09/amc
Inst Owners6.6%
Inst Owner Change-43.85%
Ins Owners38.36%
Ins Owner Change0%
Market Cap29.03M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 15.56
Fwd PE N/A
P/S 0.33
P/FCF 13.32
P/OCF 13.32
P/B 1.64
P/tB 1.85
EV/EBITDA 7.99
EPS(TTM)0.86
EY6.43%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1
FCFY7.51%
OCF(TTM)1
OCFY7.51%
SpS40.93
BVpS8.15
TBVpS7.23
PEG (NY)N/A
PEG (5Y)0.63
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 10.8%
ROCE 11.4%
ROIC 7.89%
ROICexc 19.04%
ROICexgc 25.92%
OM 2.34%
PM (TTM) 2.15%
GM 17.57%
FCFM 2.46%
ROA(3y)10.96%
ROA(5y)3.33%
ROE(3y)15.7%
ROE(5y)1.83%
ROIC(3y)5.05%
ROIC(5y)N/A
ROICexc(3y)9.78%
ROICexc(5y)N/A
ROICexgc(3y)13.54%
ROICexgc(5y)N/A
ROCE(3y)7.31%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y1.93%
ROICexc growth 3YN/A
ROICexc growth 5Y-3.61%
OM growth 3YN/A
OM growth 5Y13.97%
PM growth 3YN/A
PM growth 5Y16.86%
GM growth 3Y3.5%
GM growth 5Y1.53%
F-Score8
Asset Turnover3.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage 250
Cash Conversion 95.05%
Profit Quality 114.1%
Current Ratio 3.37
Quick Ratio 3.37
Altman-Z 8.47
F-Score8
WACC10.19%
ROIC/WACC0.77
Cap/Depr(3y)40.97%
Cap/Depr(5y)64.58%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5Y24.57%
EPS Q2Q%377.5%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.51%
Revenue growth 3Y19.72%
Revenue growth 5Y9.3%
Sales Q2Q%-18.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.3%
EBIT growth 3YN/A
EBIT growth 5Y24.57%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y217.24%
FCF growth 3YN/A
FCF growth 5Y9.41%
OCF growth 1Y229.8%
OCF growth 3YN/A
OCF growth 5Y9.14%